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Contribution
Dr. Ann Partridge identified a research question from her clinical practice and I worked closely with her to design the study: identifying inclusion/exclusion criteria for subjects and data points to collect for each subject. Dr. Javid Moslehi provided input on the cardiac aspects of the study such as defining cardiac events and important cardiac risk factors. I performed the majority of the execution of the study: obtaining institutional registry data, performing chart reviews to identify eligible patients and to collect our data points, and organizing the data in an online database. Emily Baker assisted with creating the online database. William Barry performed the majority of the statistical analyses. I wrote the original draft of the manuscript, created all the figures and tables, and all authors have read and edited the manuscript. It has been accepted for publication at the Oncologist and we are currently awaiting the proofs.
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ABSTRACT:
Background: Cardiotoxicity can be a complication of anthracycline or trastuzumab-based therapy for breast cancer patients. Screening echocardiogram (ECHO) and radionuclide ventriculogram (RVG) are often performed prior to administration of these agents to evaluate cardiac function. Limited evidence for the clinical utility of these screening tests is available.
Methods: Early-stage breast cancer patients diagnosed from 2006 to 2011 (n=1067) with a baseline ECHO/RVG were identified in a single institution prospective registry. Medical record review was performed to obtain pre-and post-ECHO/RVG treatment plans, baseline ECHO/RVG results, cardiac risk factors, and cardiac events. Patients with cardiac history were excluded. ECHO/RVG abnormalities were defined as ejection fraction (EF) <55%, valvular disease, left ventricular hypertrophy, and diastolic dysfunction. Cardiac events were defined as heart failure, myocardial infarction, arrhythmia, valvular disease, or angina during or following chemotherapy.
Results:
Among 600 eligible patients, abnormal ECHO/RVG were observed in 13 (2.2%, 1.2%-3.7%), including 9 with baseline EF <55%. There were no detected changes in treatment plans, although more frequent cardiac monitoring was recommended for 2 patients. There were no significant differences in age, race, menopausal status, smoking history, alcohol use, body mass index, or medical comorbidities between patients with abnormal and normal results. In follow-up (mean 4.0 years, range 0-8.3), 15 patients developed cardiac events (none of whom had had abnormal baseline ECHO/RVG).
Conclusions:
Baseline ECHO/RVG in patients without prior cardiac history rarely yields an abnormality that prompts change in planned anthracycline and/or trastuzumab-based treatment.
Moreover, few cardiac events developed in this screened population in follow-up. 6 
Implications for practice:
Baseline cardiac function screening with echocardiograms or radionuclide ventriculograms are frequently performed prior to administration of anthracycline-or trastuzumab-based chemotherapy in breast cancer patients due to the relatively low cost and risk to patients and the concern for potential cardiotoxicity. However, at a population level, these tests can take up time and can add up to significant costs for both patients and the healthcare system. This study finds that in patients with no history of cardiac disease, baseline cardiac function screening rarely identifies abnormalities that change treatment plans. Moreover, few cardiac events develop in an average of 4 years of follow-up, none in patients who had had abnormal baseline cardiac function screening results. This suggests that baseline cardiac function screening may have limited utility in chemotherapy planning in young breast cancer patients with no history of cardiac disease.
INTRODUCTION
Anthracyclines and trastuzumab are two very effective systemic therapy agents widely used to treat breast cancer. However, they are associated with risk of adverse cardiovascular complications including cardiac dysfunction and heart failure. [1] [2] [3] [4] [5] [6] Baseline cardiac screening may help avoid cardiotoxicity by detecting pre-existing cardiac conditions, resulting in more frequent cardiac monitoring, administration of cardioprotective medications, and/or modification of planned cancer therapy. Therefore, the American College of Cardiology (ACC), American Heart Association (AHA), and American Society of Nuclear Cardiology suggest that patients be screened for pre-existing cardiac conditions prior to potentially cardiotoxic chemotherapy. Echocardiograms (ECHOs) and radionuclide ventriculograms (RVGs, also known as multi-gated acquisition, MUGA, scans) both provide a quantitative measure of cardiac function, the left ventricular ejection fraction (LVEF). Because of the noninvasive nature and broad availability of these exams, they are widely utilized for cardiac screening prior to chemotherapy. 3 Studies have estimated that between 60% and 80% of patients receive baseline cardiac evaluation with RVGs prior to chemotherapy, suggesting variation in implementation of the ACC and AHA recommendation. [8] [9] Limited prior research suggests that ECHOs and RVGs infrequently reveal clinically significant results that affect oncology treatment plans in this population. [8] [9] [10] [11] In one study of 198 adults, RVGs were conducted in 80% of breast cancer patients undergoing adjuvant chemotherapy, with only 2.5% of RVGs indicating cardiac abnormalities, all in smokers. 9 Baseline ECHO results and potential effects of screening on treatment planning in patients undergoing trastuzumab therapy 8 have not yet been studied. In addition, a significant portion of patients may have neither cardiac symptoms nor underlying cardiac disease; the utility of baseline cardiac function testing in these patients is unclear. In an effort to understand the utility of baseline cardiac function testing, we conducted a study of women who underwent baseline cardiac screening prior to adjuvant chemotherapy for breast cancer at our institution from 2006 to 2011 to determine how often abnormal ECHO or RVG results changed initial treatment plans, and whether abnormal screening tests were associated with cardiac events during and after chemotherapy.
MATERIALS AND METHODS
We conducted a retrospective analysis of a prospectively collected cohort of newly diagnosed early-stage (stages I-III) female breast cancer patients cared for at Dana-Farber Cancer Institute previous history of chemotherapy (n = 9), c) previous history of radiation therapy (n = 15), d) 9 known cardiac history, defined as diagnosis of myocardial infarction cardiomyopathy, or congestive heart failure (CHF) in institutional registry or medical record review (n = 32), since history of chemotherapy, radiation therapy, and cardiac disease are indications for cardiac function assessment and no longer for screening; e) history of prior cardiac imaging with available results, as these results can influence treatment planning (n = 78), f) no chemotherapy ever indicated in initial treatment discussions so cardiac function screening would not be performed (n = 18), and g) no ECHO/RVG results available in our medical record system (n = 26 We defined a cardiac event in follow-up as symptomatic heart failure, myocardial infarction, arrhythmia, valvular disease (as defined above), or coronary artery disease and correlated it to cardiac imaging including RVG, ECHO, and EKGs when available. The length of follow-up is defined as the start date of chemotherapy to the date of the last clinic visit or the date of diagnosis of recurrence or metastasis. We excluded follow-up data after recurrence or metastasis because patients often underwent additional chemotherapy.
This study was approved by the DFCI institutional review board, and all patients had previously signed informed consent forms to participate in the institutional registry and medical record review studies.
RESULTS
For the original 1067 patients with baseline ECHOs, RVGs, or EKGs identified in the registry, the median age was 56 years (range 25-91 years) (see Figure 1 for study cohort flow diagram).
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Among the 600 patients included in the analytic sample, the median age was 48 years (range 23-80). In pre-cardiac screening, 79% of treatment plans included anthracycline, 34% included trastuzumab, and 16% included both. ECHOs were performed in 74 of the 600 patients (12.3%) and RVGs in the remaining 526, as per institutional conventions during the study period.
Abnormal ECHO and RVG results were observed in thirteen of the 600 patients (2.2%, 95%
confidence interval: 1.2%-3.7%), including ten with baseline LVEF <55%, with the lowest at 50% (Figure 2) . The other three patients had atrial or ventricular size or thickness abnormalities on ECHO. Four of these thirteen patients received ECHOs, while the other nine received RVGs.
No changes in treatment plan, such as switching to a less cardiotoxic agent or changes in cardiac medications, were made for any of the thirteen patients. However, two patients were recommended to and received more frequent cardiac function assessment via RVG or ECHO and close follow-up with their provider to evaluate for symptoms of cardiac dysfunction. These two patients were relatively young (ages 39 and 49), never smokers, light alcohol drinkers (<1 drink per week), and postmenopausal due to hysterectomy and oophorectomy. One had a BMI of 18.0, while the other had a BMI of 35.6, which were the extremes of the patients with abnormal cardiac screening results. They developed no cardiac events in follow-up.
Analysis of basic demographics between patients with abnormal versus normal cardiac screening results showed no statistically significant differences (p > 0.05) in age, race, menopausal status, smoking history, alcohol use, BMI, or medical comorbidities including hypertension, diabetes, and hyperlipidemia (Table 1) . Given the infrequency of abnormal results, further statistical analysis to determine potential predictors of abnormal results was not pursued. 12 Of the 600 patients, 546 (91%) completed their course of chemotherapy. 24 patients (3.8%) did not complete anthracyclines or trastuzumab chemotherapy due to toxicity, 17 due to anthracycline toxicity, 11 due to trastuzumab toxicity, with 4 with toxicity to both agents. The remaining 30 patients did not complete chemotherapy due to toxicity to paclitaxel (21, 3.5%), reaction to carboplatin (1, 0.2%), neutropenia (1, 0.2%) disease progression (3, 0.5%), transfer of care to another hospital (1, 0.2%), patient preference (1, 0.2%), and persistent reduction in LVEF (2, 0.3%). Only two patients with abnormal baseline screening did not complete chemotherapy, both due to toxicity to paclitaxel.
All 600 patients were followed for cardiac events with median follow-up of 4.0 years (range 0 to 8.3 years). Sixty-six patients (11%) developed recurrent or metastatic disease. Fifteen patients (2.5%) were found to have cardiac events (Table 2 ). These included two cases of symptomatic heart failure, nine cases of new arrhythmias such as supraventricular tachycardia and atrial fibrillation, four cases of valvular disease, and one case of angina with coronary artery disease on catheterization. One patient developed heart failure followed by tricuspid regurgitation. As above, the infrequency of abnormal baseline cardiac findings precluded further analysis to identify predictors of cardiac events. Of note, none of the patients with abnormal baseline cardiac results developed cardiac events.
DISCUSSION
Baseline cardiac screening is commonly performed to assess for pre-existing cardiac dysfunction in women planning for chemotherapy or trastuzumab therapy. However, detection of 13 abnormalities is infrequent and has little effect on treatment recommendations or subsequent cardiac events in a population of breast cancer survivors. The results of our analysis call into question the utility of baseline pretreatment cardiac evaluation in women without cardiac history for whom systemic chemotherapy with potentially cardiotoxic agents is planned.
The results of our analysis confirm and expand upon prior research in this area. Sabel et al.
conducted a retrospective study of 296 patients with breast cancer, 62 of whom had prechemotherapy RVGs, and showed a 6.5% rate of low LVEF (between 49% and 51%, low LVEF defined as <51%). found that in 7 years of follow-up in a randomized trial, 4.0% of patients developed cardiac events after receiving anthracyclines and trastuzumab compared to 1.3% in patients receiving anthracyclines only. Risk factors associated with development of CHF include baseline LVEF 50% to 54%, age (2.3% in <50 years, 5.5% in 50-59 years, and 6.1% in ≥60 years), and antihypertensive medications at baseline.
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Our analysis represents the largest study to assess the utility of baseline cardiac function evaluation in systemic treatment planning for breast cancer patients considering potentially cardiotoxic systemic therapy and is the first to evaluate this among patients planned to receive trastuzumab therapy. Further, our study is the first to show the low risk of subsequent cardiac events in follow-up and the lack of association between prior abnormal cardiac screening and subsequent cardiac events, adding new evidence to reconsider the routine practice of baseline cardiac function screening in this setting.
Our findings should be interpreted in consideration of several potential limitations. Although most of our study data were prospectively collected, our analysis was retrospective and may be subject to biases common to retrospective studies. Subgroup analysis to determine whether a difference exists in threshold to treat with anthracyclines versus trastuzumab could not be performed. Trastuzumab was discussed with many patients at the initial clinic visit because final pathology results were not yet available. However, at the post-cardiac screening visit, when HER2 status was known, HER2 negative patients no longer required trastuzumab and further conversation about this agent did not occur, and this was not considered a change in therapy plan 15 based on the baseline cardiac screening. Furthermore, our final study cohort was relatively young with a mean age of 48 years, which may limit the generalizability of our findings to older patient populations even though our study population included patients as old as 80 years. As noted in our results, the average age of our entire cohort was 57, which decreased to 48 after patients were excluded. Thus, patients excluded from analysis due to prior cardiac history, cardiac imaging, chemotherapy or radiation therapy were older on average (mean age of the 467 excluded patients was 68.5 years, with ages ranging from 25 to 91 years). It is also worth noting that the majority of the patients seen at our institution did not have baseline cardiac screening, Abnormal results were observed in 13 (2.17%, 1.2%-3.7%) of 600 patients. Of these abnormal results, none led to changes in treatment decisions (e.g., switching to a less cardiotoxic agent), though 2 patients (15.4%, 1.9%-45.5%) received increased monitoring of cardiac function throughout and after treatment.
Table 1. Cohort Characteristics
There were no statistically significant differences (p > 0.05) between the patients with abnormal and normal cardiac screening results. Of note, some patients may have multiple comorbidities while others have no comorbidities so percentages do not add up to 100 and are solely the proportion of patients in that group with that particular comorbidity. Table 2 . Cardiac events observed in follow-up.
Sixteen cardiac events were identified during follow-up. Of note, one patient had two cardiac events that were diagnosed at different times.
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Figure and 
Figure 2. Impact of cardiac function screening on treatment decision-making
Abnormal results were observed in 13 (2.17%, 1.2%-3.7%) of 600 patients. Of these abnormal results, none led to changes in treatment decisions (e.g., switching to a less cardiotoxic agent), though 2 patients (15.4%, 1.9%-45.5%) received increased monitoring of cardiac function throughout and after treatment.
Table 1. Cohort Characteristics
Sixteen cardiac events were identified during follow-up. Of note, one patient had two cardiac events that were diagnosed at different times. 
